UK Markets close in 5 hrs 2 mins

Merus N.V. (MRUS)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
26.01-2.52 (-8.83%)
At close: 04:00PM EST
26.01 0.00 (0.00%)
After hours: 04:40PM EST
Full screen
Trade prices are not sourced from all markets
Previous close28.53
Open28.54
Bid0.00 x 800
Ask0.00 x 1100
Day's range24.69 - 26.33
52-week range15.68 - 33.00
Volume445,260
Avg. volume525,691
Market cap997.473M
Beta (5Y monthly)0.64
PE ratio (TTM)N/A
EPS (TTM)-2.55
Earnings date03 Nov 2021 - 08 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est30.63
  • Globe Newswire

    Merus to Participate in a Fireside Chat at the Jefferies London Healthcare Conference (Virtual)

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., Chief Executive Officer of Merus, will participate in a fireside chat at the Jefferies London Healthcare Conference (Virtual). The prerecorded fireside chat will be available starting on Thursday, November 18, 2021 at 8:00 am

  • Simply Wall St.

    Could The Merus N.V. (NASDAQ:MRUS) Ownership Structure Tell Us Something Useful?

    If you want to know who really controls Merus N.V. ( NASDAQ:MRUS ), then you'll have to look at the makeup of its share...

  • Globe Newswire

    Merus Announces Pricing of Public Offering of Common Shares

    UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced the pricing of an underwritten public offering of 3,859,650 common shares, at a public offering price of $28.50 per share (the “Offer Shares”). Merus also granted the underwriters a 30-day option to purchase up